Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1661-1665

  Moreillon, Philippe ^a   Wilson, Walter R ^b   Leclercq, Roland ^c   Entenza, Jose M ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Mayo Clinic College of Medicine   (United States)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; LINEZOLID; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; UNITED KINGDOM; UNITED STATES; UROGENITAL SYSTEM;

ACETAMIDES; ADMINISTRATION, ORAL; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; RATS; RATS, WISTAR; VANCOMYCIN RESISTANCE;

EID: 34248350689     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00744-06     Document Type: Article

References (50)

1. Anderson, D. J., L. Olaison, J. R. McDonald, J. M. Miro, B. Hoen, C. Selton-Suty, T. Doco-Lecompte, E. Abrutyn, G. Habib, S. Eykyn, P. A. Pappas, V. G. Fowler, D. J. Sexton, M. Almela, G. R. Corey, and C. H. Cabell. 2005. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the International Collaboration on Endocarditis-merged database. Eur. J. Clin. Microbiol. Infect. Dis. 24:665-670.
2. Andes, D., and W. A. Craig. 2003. Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47:3935-3941.
3. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
4. Athanassopoulos, G., A. Pefanis, V. Sakka, D. Iliopoulos, D. Perrea, and H. Giamarellou. 2006. Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis. Antimicrob. Agents Chemother. 50:654-657.
5. Bayer, A. S., and J. Tu. 1990. Chemoprophylactic efficacy against experimental endocarditis caused by β-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob. Agents Chemother. 34:1068-1074.
6. Blouin, R. A., L. A. Bauer, D. D. Miller, K. E. Record, and W. O. Griffen, Jr. 1982. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21:575-580.
7. Bugnon, D., G. Potel, J. Caillon, D. Baron, H. B. Drugeon, P. Feigel, and M. F. Kergueris. 1998. In vivo simulation of human pharmacokinetics in the rabbit. Bull. Math. Biol. 60:545-567.
8. Bugnon, D., G. Potel, Y. Q. Xiong, J. Caillon, M. F. Kergueris, P. Le Conte, D. Baron, and H. Drugeon. 1996. In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Antimicrob. Agents Chemother. 40:1164-1169.
9. Burkhardt, O., K. Borner, N. von der Hoh, P. Koppe, M. W. Pletz, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50:707-712.
10. Chow, J. W. 2000. Aminoglycoside resistance in enterococci. Clin. Infect. Dis. 31:586-589.
11. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
12. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
13. Dajani, A. S., R. E. Bawdon, and M. C. Berry. 1994. Oral amoxicillin as prophylaxis for endocarditis: what is the optimal dose? Clin. Infect. Dis. 18:157-160.
14. Dajani, A. S., K. A. Taubert, W. Wilson, A. F. Bolger, A. Bayer, P. Ferrieri, M. H. Gewitz, S. T. Shulman, S. Nouri, J. W. Newburger, C. Hutto, T. J. Pallasch, T. W. Gage, M. E. Levison, G. Peter, and G. Zuccaro, Jr. 1997. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin. Infect. Dis. 25:1448-1458.
15. Danchin, N., X. Duval, and C. Leport. 2005. Prophylaxis of infective endocarditis: French recommendations 2002. Heart 91:715-718.
16. Dankert, J., J. van der Werff, S. A. Zaat, W. Joldersma, D. Klein, and J. Hess. 1995. Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect. Immun. 63:663-671.
17. Dhawan, V. K., A. S. Bayer, and M. R. Yeaman. 2000. Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 44:3206-3209.
18. Dhawan, V. K., M. R. Yeaman, and A. S. Bayer. 1999. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis. J. Infect. Dis. 180:1561-1568.
19. Dube, L., J. Caillon, C. Gras-Le Guen, C. Jacqueline, M.-F. Kergueris, J.-C. Granry, G. Potel, and D. Bugnon. 2003. Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model. Antimicrob. Agents Chemother. 47:3663-3666.
20. Durack, D. T., and R. G. Petersdorf. 1973. Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens. J. Clin. Investig. 52:592-598.
21. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1662-1667.
22. Fernández-Guerrero, M. L., L. Herrero, M. Bellver, I. Gadea, R. F. Roblas, and M. de Gorgolas. 2002. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. J. Intern. Med. 252:510-515.
23. Fluckiger, U., P. Francioli, J. Blaser, M. P. Glauser, and P. Moreillon. 1994. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J. Infect. Dis. 169:1397-1400.
24. Fluckiger, U., P. Moreillon, J. Blaser, M. Bickle, M. P. Glauser, and P. Francioli. 1994. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob. Agents Chemother. 38:2846-2849.
25. Francioli, P., P. Moreillon, and M. P. Glauser. 1985. Comparison of single doses of amoxicillin or of amoxicillin-gentamicin for the prevention of endocarditis caused by Streptococcus faecalis and by viridans streptococci. J. Infect. Dis. 152:83-89.
26. Glauser, M. P., J. P. Bernard, P. Moreillon, and P. Francioli. 1983. Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J. Infect. Dis. 147:568-575.
27. Grisetti, M., A. Brundusino, H. Vasconcellos Lopes, H. J. Lai, and C. Oliani. 1996. Pharmacokinetic profile of three different daily dosages of amoxicillin. Eur. Bull. Drug Res. 7:15-20.
28. Hall, G., A. Heimdahl, and C. E. Nord. 1999. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin. Infect. Dis. 29:1-8.
29. Héraïef, E., M. P. Glauser, and L. R. Freedman. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131.
30. Jacob, A. E., and S. J. Hobbs. 1974. Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J. Bacteriol. 117:360-372.
31. Mercier, R. C., M. J. Rybak, A. S. Bayer, and M. R. Yeaman. 2000. Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis. Infect. Immun. 68:4699-4705.
32. Miro, J. M., F. Marco, C. Garcia de la Maria, A. del Rio, J. Gavalda, M. Almela, Y. Armero, M. E. Diaz, D. Soy, A. Moreno, A. Pahissa, J. M. Gatell, and M. T. Jimenez de Anta. 2000. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 669, p. 49.
33. Moellering, R. C. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138:135-142.
34. Moreillon, P. 2000. Endocarditis prophylaxis revisited: experimental evidence of efficacy and new Swiss recommendations. Swiss Working Group for Endocarditis Prophylaxis. Schweiz. Med. Wochenschr. 130:1013-1026.
35. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721.
36. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
37. Olaison, L., and K. Schadewitz. 2002. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin. Infect. Dis. 34:159-166.
38. Oprea, S. F., N. Zaidi, S. M. Donabedian, M. Balasubramaniam, E. Hershberger, and M. J. Zervos. 2004. Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis. J. Antimicrob. Chemother. 53:626-630.
39. Pelletier, L. L., Jr., D. T. Durack, and R. G. Petersdorf. 1975. Chemotherapy of experimental streptococcal endocarditis. IV. Further observations on prophylaxis. J. Clin. Investig. 56:319-330.
40. Rayner, C. R., A. Forrest, A. K. Meagher, M. C. Birmingham, and J. J. Schentag. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411-1423.
41. Redington, J., S. C. Ebert, and W. A. Craig. 1991. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. Rev. Infect. Dis. 13(Suppl. 10):S790-S799.
42. Reynolds, R., N. Potz, M. Colman, A. Williams, D. Livermore, and A. MacGowan on behalf of the BSAC Extended Working Party on Bacteraemia Resistance Surveillance. 2004. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. 53:1018-1032.
43. Shanson, D. C., R. F. Ashford, and J. Singh. 1980. High-dose oral amoxycillin for preventing endocarditis. Br. Med. J. 280:446.
44. Simmons, N. A. 1993. Recommendations for endocarditis prophylaxis. The Endocarditis Working Party for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 31:437-438.
45. Stevens, M. P., and M. B. Edmond. 2005. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin. Infect. Dis. 41:1134-1142.
46. Sullam, P. M., U. Frank, M. R. Yeaman, M. G. Tauber, A. S. Bayer, and H. F. Chambers. 1993. Effect of thrombocytopenia on the early course of streptococcal endocarditis. J. Infect. Dis. 168:910-914.
47. Vermot, D., J. M. Entenza, J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1996. Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis. Antimicrob. Agents Chemother. 40:809-811.
48. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
49. Xiong, Y. Q., M. R. Yeaman, and A. S. Bayer. 1999. In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. Antimicrob. Agents Chemother. 43:1111-1117.
50. Yeaman, M. R. 1997. The role of platelets in antimicrobial host defense. Clin. Infect. Dis. 25:951-968.